Project description:Two synthetic bacterial consortia (SC) composed by bacterial strains isolated from a natural phenanthrene-degrading consortium (CON), Sphingobium sp. AM, Klebsiella aerogenes B, Pseudomonas sp. Bc-h and T, Burkholderia sp. Bk and Inquilinus limosus Inq were grown in LMM supplemented with 200 mg/L of phenanthrene (PHN) during 72 hours in triplicate.
Project description:Over the last 10 years, technological advances in molecular biology enabled a more accurate genomic characterization of tumors. For each tumor location, this led to the identification of subgroups with similar molecular characteristics. This identification allowed the development of targeted therapies and thus to improve the patient prognosis. This molecular characterization has also revealed the tumor heterogeneity. It may be the cause of treatment resistance and therefore of relapses. Additionally, tumor cells are in constant dialogue with their microenvironment composed of different immune or non immune cells. This microenvironment is now targeted in cancer treatment.
To date, there are few studies that combine a deep genomic characterization of both tumor and tumor microenvironment of the patient. Combining the two types of studies on the same tumor should help to define new therapeutic targets and should allow a combination of targeted and immunomodulatory therapies. To this end, our project is to conduct an exhaustive integrated exploratory analysis at genomic, transcriptomic and immunological levels of 3 tumor types (in colon, kidney and liver cancer).
